User: Guest  Login
Title:

Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.

Document type:
Journal Article
Author(s):
Haas, S
Abstract:
Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE), prevention of stroke in patients with atrial fibrillation (AF) and secondary prevention in patients with acute coronary syndrome (ACS). There is a clinical need for novel anticoagulants offering improvements over current standard of care, such as fixed oral dosing and no need for routine monitoring. Rivaroxaban, an oral, once-daily, direct Factor Xa inhibitor, has recently completed the RECORD phase...     »
Journal title abbreviation:
Eur J Haematol
Year:
2009
Journal volume:
82
Journal issue:
5
Pages contribution:
339-49
Language:
eng
Fulltext / DOI:
doi:10.1111/j.1600-0609.2009.01230.x
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/19187276
Print-ISSN:
0902-4441
TUM Institution:
Institut für Experimentelle Onkologie und Therapieforschung
 BibTeX